One-year follow-up data from a first-in-human study of 23 glaucoma patients implanted with SpyGlass Pharma’s intraocular lens (IOL)–based drug delivery platform with bimatoprost at the time of cataract surgery showed enduring and consistent IOP reduction at 3 dose strengths. There was a mean pressure reduction of 44.6% at month 12 compared to preoperative washed-out baseline levels, and all patients sustained more than a 20% IOP reduction from baseline and IOPs of ≤18 mmHg through month 12, according to data presented at ASCRS.

“SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO of SpyGlass Pharma, in a news release. "There are nearly 5 million annual cataract procedures in the United States, approximately 20% of them are performed in patients with glaucoma or ocular hypertension. The unmet need is significant, and SpyGlass is committed to delivering safe and effective therapeutics via proven implantation techniques to improve the lives of patients living with chronic eye conditions. The compelling clinical data ... suggest we are on track to bringing our innovative platform to patients.”  

The IOL is designed to deliver 3 years of bimatoprost to targeted tissues.